


## Floctafenine

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-A0259  |
| <b>CAS No.:</b>           | 23779-99-9  |
| <b>Molecular Formula:</b> | C <sub>20</sub> H <sub>17</sub> F <sub>3</sub> N <sub>2</sub> O <sub>4</sub>              |
| <b>Molecular Weight:</b>  | 406.36  |
| <b>Target:</b>            | COX   |
| <b>Pathway:</b>           | Immunology/Inflammation   |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |  |       |
|-------------------------------------|--|-------|
| <b>Description</b>                  | Floctafenine, a nonsteroidal anti-inflammatory agent (NSAID), acts as an effective analgesic agent <sup>[1][2]</sup> . Floctafenine is an inhibitor of COX-1 and COX-2 activities in vitro, showing a slightly higher potency towards COX-1. Floctafenine is used for the research of short term pain research <sup>[3]</sup> .  |       |
| <b>IC<sub>50</sub> &amp; Target</b> | COX-1  | COX-2 |
| <b>In Vitro</b>                     | <p>Floctafenine (0.1-100 μM; in the presence of LPS; 24 hours) is slightly more potent 1.5-fold to inhibit in vitro platelet COX-1 than monocyte COX-2. The IC<sub>50</sub> values for platelet COX-1 and monocyte COX-2 inhibition are 2.33 μM (95%CI) and 3.47 μM (95%CI), respectively in heparinized whole blood samples<sup>[3]</sup>.</p> <p>Floctafenine (0.1-100 μM; in the presence of A23187; 1 hour) does not significantly affect A23187-caused LTB<sub>4</sub> generation even up to 100 μM<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |       |
| <b>In Vivo</b>                      | <p>Floctafenine (intraperitoneal injection; 50 mg/kg; single dose; 30 minutes prior to p-benzoquinone) has an inhibitory effects on p-benzoquinone-induced writhing in rats, inhibition of writhing is 65.98%<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>  |       |

### REFERENCES

- [1]. P Giuseppe, et al. Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. *Ann Allergy Asthma Immunol.* 1997 Jan;78(1):74-8.
- [2]. Gehan Hegazy Hegazy, et al. Synthesis of some floctafenine derivatives of expected anti-inflammatory/analgesic activity. *Arch Pharm (Weinheim).* 2005 Aug;338(8):378-84.
- [3]. R Maenthaisong, et al. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. *Int J Immunopathol Pharmacol.* Apr-Jun 2013;26(2):403-17.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA